LifeSprout

LifeSprout

Develops soft tissue restoration products

Overview

LifeSprout develops soft tissue restoration products for the aesthetic and reconstructive medicine markets. Its products are designed to mimic natural tissues and support tissue replacement and regeneration, using advances in materials science to achieve tissues that look and behave like real tissue with minimal downtime for patients. The technology is delivered to patients through healthcare providers and clinics, enabling cosmetic enhancements and reconstructive procedures for soft tissue loss caused by aging, cancer, or metabolic diseases. LifeSprout differentiates itself by leveraging Johns Hopkins–connected scientific and surgical expertise to create tissue-like materials tailored for both cosmetic and medical use, focusing on regenerative approaches rather than simple implants. The company’s goal is to offer practical, reliable soft tissue solutions that improve form and function for patients, expanding access to high-quality regenerative and aesthetic treatments.

About LifeSprout

Simplify's Rating
Why LifeSprout is rated
C+
Rated B on Competitive Edge
Rated C on Growth Potential
Rated C on Differentiation

Industries

Biotechnology

Healthcare

Company Size

11-50

Company Stage

Series A

Total Funding

$35.8M

Headquarters

Baltimore, Maryland

Founded

2015

Get referred to LifeSprout

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Lumina met its pivotal endpoint against Restylane Defyne and showed no product-related SAEs.
  • LifeSprout filed CE Mark on January 23, 2025, aiming for late-2025 approval.
  • Career postings on September 3, 2026 show active hiring for R&D and process development.

What critics are saying

  • Lumina remained investigational on September 3, 2026, with no approved revenue product.
  • Europe’s CE Mark review still blocks commercialization beyond the January 23, 2025 filing.
  • Restylane Defyne and larger aesthetics rivals can outspend LifeSprout before approvals; failure kills the company.

What makes LifeSprout unique

  • Johns Hopkins founders built LifeSprout’s biomimetic Regenerative Matrix around soft-tissue science.
  • Lumina combines hyaluronic acid safety with biostimulatory, biodegradable tissue restoration.
  • Boyang Trading license extends Lumina into Greater China, validating international commercial interest.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$35.8M

Above

Industry Average

Funded Over

4 Rounds

Series A funding typically happens when a startup has a product and some customers, and now needs funding to scale. This money is usually used to grow the team, expand marketing, and improve the product. Venture capital firms are frequently the main investors here.
Series A Funding Comparison
Above Average

Industry standards

$15M
$8.2M
Discord
$15M
Canva
$28.5M
LifeSprout
$30M
Kalshi

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

Paid Holidays

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-4%
Technical.ly
Feb 12th, 2024
The Incredible Evolution Of Baltimore And Dc Tech, From 2009 Into The Future

This is a guest post by Dave Carberry, founder of Enradius and Needworking.com, written as part of a series celebrating Technical.ly’s 15th anniversary. Full disclosure: This article mentions Fearless, a Technical.ly Talent Builder client, and Spark Baltimore, where Technical.ly has coworking space. Neither relationship had any impact on this report.In the ever-evolving landscape of technology and innovation, milestones are not just markers of time. They represent the progress, challenges, and triumphs of a community. As Technical.ly celebrates its 15th anniversary, I wanted a moment to reflect on the incredible journey and dynamic changes that have shaped the Baltimore and Washington tech scenes over the past decade and a half

StreetInsider
Jan 31st, 2024
LifeSprout Enters into Licensing Agreement with Boyang Trading to Develop and Commercialize Next-Generation Lumina(TM) Dermal Filler in Greater China

LifeSprout enters into licensing agreement with Boyang Trading to develop and commercialize next-generation Lumina(TM) dermal filler in Greater China.

Business Wire
Nov 18th, 2021
LifeSprout hired Michael Kranda as CEO and member of the board of directors on Nov 18th 21'.

LifeSprout, Inc., a privately held regenerative medicine company founded with technology licensed from Johns Hopkins University, today announced the appointment of Michael Kranda as CEO and member of the board of directors.

Recently Posted Jobs

Sign up to get curated job recommendations

LifeSprout is Hiring for 1 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →